Precision oncology approaches have made great strides harnessing individual tumor mutation profiles to guide targeted therapy choices. However, deeper molecular insights are needed to improve personalized treatment decisions that are tailored to specific molecular characteristics of a tumor. Integrating gene expression analysis in personalized oncology provides an additional level of insight that cannot be provided by genomic data alone. These analyses include evaluating expressed mutations and drug targets, novel gene fusions, clinically relevant signatures, and the tumor immune microenvironment (TME).

Comprehensive Molecular Tumor Analysis (CMTA) is a NGS-based innovative tumor diagnostic test developed by Alacris Theranostics. The test integrates whole exome and transcriptomic sequencing (WES and RNAseq) and is deployed as an end-to-end accredited diagnostic platform from tumor sample uptake (FFPE or frozen) to personalized clinical interpretation report. Designed to serve all cancer patients, CMTA is a tumor-agnostic test that displays a unique molecular view into each individual sample, which is particularly well-suited to refractory cancers with complex patterns or tumors of unknown origin.

In this webinar, Alacris Theranostics will discuss the benefits of comprehensive tumor profiling in clinical settings and present the strategy implemented in their bioinformatics pipeline to identify cancer-relevant somatic events. In addition, the diagnostic company will share how they use QIAGEN Clinical Insight (QCI) Interpret to annotate variants and identify potential therapeutic entry-points.

About the speaker
Marie-Laure Yaspo, PhD, Co-Founder and Chief Scientific Officer
Alacris Theranostics
Marie-Laure Yaspo is the co-founder and chief scientific officer of Alacris Theranostics, a systems medicine company that specializes in the development of innovative approaches for cancer precision medicine, offering best-in-class accredited comprehensive molecular tumor diagnostics. Yaspo is also a research group leader at the Max Planck Institute for Molecular Genetics (MPIMG, Berlin) where she heads the Otto Warburg Laboratory “Gene Regulation and Systems Biology of Cancer” at MPIMG. She coordinated the International Consortium for mapping and sequencing human chromosome 21 within the Human Genome Project. Yaspo participated in the International Cancer Genome and the European Blueprint projects. In addition, she coordinated the data analysis within the Innovative Medicines Initiative Oncotrack project. She also coordinated Treat20Plus, a translational study carried out together with the Charité Comprehensive Cancer Center in Berlin, aimed at optimizing the treatment of patients with metastatic melanoma. Yaspo completed her postdoctoral research at the Imperial Cancer Research Fund in London.
Date of recording:Tuesday, December 5, 2023
Duration:60 minutes
Human Genetics
Bioinformatics - Interpretation
Cancer Research